Clinical trial
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
NCT00367835 · Shire, Industry · Completed
Key facts
| NCT number | NCT00367835 |
|---|---|
| Title | SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms |
| Official title | A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | ADHD |
| Intervention type | Drug |
| Interventions | SPD503 (Guanfacine hydrochloride), Placebo |
| Enrollment | 217 |
| Start date | Dec 4, 2006 |
| Primary completion | Jan 4, 2008 |
| Completion | Jan 4, 2008 |
| First posted | Aug 23, 2006 |
| Last update posted | Jun 14, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: